CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Early-stage hepatocellular carcinoma (E-HCC) is being diagnosed increasingly, and in one half of diagnosed patients, recurrence will develop. Thus, it is urgent to identify recurrence-related markers. We investigated the effectiveness of CpG methylation in predicting recurrence for patients with E-HCCs. Patients and Methods: In total, 576 patients with E-HCC from four independent centers were sorted by three phases. In the discovery phase, 66 tumor samples were analyzed using the Illumina Methylation 450k Beadchip. Two algorithms, Least Absolute Shrinkage and Selector Operation and Support Vector Machine-Recursive Feature Elimination, were used to select significant CpGs. In the training phase, penalized Cox regression was used to further narrow CpGs into 140 samples. In the validation phase, candidate CpGs were validated using an internal cohort (n = 141) and two external cohorts (n = 191 and n =104). Results: After combining the 46 CpGs selected by the Least Absolute Shrinkage and Selector Operation and the Support Vector Machine-Recursive Feature Elimination algorithms, three CpGs corresponding to SCAN domain containing 3, Src homology 3-domain growth factor receptor-bound 2-like interacting protein 1, and peptidase inhibitor 3 were highlighted as candidate predictors in the training phase. On the basis of the three CpGs, a methylation signature for E-HCC (MSEH) was developed to classify patients into high- and low-risk recurrence groups in the training cohort ( P < .001). The performance of MSEH was validated in the internal cohort ( P < .001) and in the two external cohorts ( P < .001; P = .002). Furthermore, a nomogram comprising MSEH, tumor differentiation, cirrhosis, hepatitis B virus surface antigen, and antivirus therapy was generated to predict the 5-year recurrence-free survival in the training cohort, and it performed well in the three validation cohorts (concordance index: 0.725, 0.697, and 0.693, respectively). Conclusion: MSEH, a three-CpG–based signature, is useful in predicting recurrence for patients with E-HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Power failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641
Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000710 · Cited by 903 · cited 1×
“However, one half of patients with E-HCC will develop recurrence after resection, rendering the 5-year survival rate, 30%.(4) Therefore, E-HCC is a heterogeneous group, comprising different subsets with distinct outcomes.”
BackgroundGenome-wide DNA methylation profiles in hepatocellular carcinoma
Shen, J., Wang, S., Zhang, Y.-J., Kappil, M., Wu, H.-C., Kibriya, M. G., Wang, Q., Jasmine, F., Ahsan, H., Lee, P.-H., et al. (2012) · Hepatology · doi:10.1002/hep.25569 · Cited by 196 · cited 1×
“The first study used the Illumina 27K Beadchip on 62 HCCs to search for predictive markers at a single center.(14) Three other studies(12,13,33) also used methylation arrays to A B”
Method
Cited by
Li, Y., Ge, D., & Lu, C. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0316-3 · Cited by 285
Self-citationJiang, C., Department of Cardiology, T. F. A. H. O. G. M. U., Jiang, W., & Department of Cardiology, N. T. C. M. H. (2022) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2022174 · Cited by 5
Metadata
- Authors
- Qiu, J., Peng, B., Tang, Y., Qian, Y., Guo, P., Li, M., Luo, J., Chen, B., Tang, H., Lu, C., Cai, M., Ke, Z., He, W., Zheng, Y., Xie, D., Li, B., & Yuan, Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-03-01
- Volume
- 35
- Issue
- 7
- Pages
- 734-742
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2578808164
- Cited by
- 172
- References
- 3
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.